DBV Technologies (NASDAQ:DBVT) Cut to “Sell” at Wall Street Zen

DBV Technologies (NASDAQ:DBVT) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Several other brokerages also recently commented on DBVT. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a research note on Monday, December 29th. Guggenheim reiterated a “buy” rating and set a $51.00 price target on shares of DBV Technologies in a research report on Friday. Citizens Jmp increased their price target on shares of DBV Technologies from $45.00 to $47.00 and gave the stock a “market outperform” rating in a report on Friday. Cantor Fitzgerald set a $48.00 price objective on shares of DBV Technologies in a research note on Wednesday, December 17th. Finally, Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $38.65.

DBV Technologies Price Performance

NASDAQ:DBVT opened at $20.00 on Friday. The company has a market cap of $1.11 billion, a P/E ratio of -3.83 and a beta of -0.97. The stock’s fifty day moving average price is $21.58 and its two-hundred day moving average price is $17.22. DBV Technologies has a 1 year low of $5.30 and a 1 year high of $26.18.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.96). DBV Technologies had a negative net margin of 2,606.83% and a negative return on equity of 310.56%. The company had revenue of $0.64 million during the quarter, compared to analysts’ expectations of $1.06 million. On average, analysts expect that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

A number of hedge funds and other institutional investors have recently bought and sold shares of DBVT. Allworth Financial LP bought a new position in shares of DBV Technologies in the 4th quarter worth $32,000. Royal Bank of Canada bought a new stake in shares of DBV Technologies during the 4th quarter worth $34,000. New York State Common Retirement Fund purchased a new position in DBV Technologies in the third quarter worth $34,000. GAMMA Investing LLC grew its position in DBV Technologies by 38.4% in the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after acquiring an additional 744 shares in the last quarter. Finally, Truvestments Capital LLC increased its stake in DBV Technologies by 71.3% in the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after acquiring an additional 1,620 shares during the last quarter. Hedge funds and other institutional investors own 71.74% of the company’s stock.

More DBV Technologies News

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: VIASKIN peanut patch nearing FDA submission — media coverage highlights management preparing for a BLA/approval pathway and positions the peanut patch as a potential near-term commercial catalyst. DBV Technologies sets stage for ‘swift’ success as breakthrough peanut patch nears FDA submission
• Positive Sentiment: Citizens Jmp raised its price target to $47 and assigned a “market outperform” rating, signaling strong analyst conviction and implying substantial upside from current levels. Citizens Jmp price target raise
• Positive Sentiment: Guggenheim reaffirmed a “buy” rating and set a $51 price target, another high-end analyst endorsement that supports the bullish narrative around the peanut patch program. Guggenheim reiterates buy
• Positive Sentiment: Financial and operational update: DBV reports progress in toddler and child VIASKIN trials, strengthened leadership ahead of BLA submission, and disclosed cash of $194M plus $94M of additional proceeds (funding into Q2 2027) — improving near-term runway for regulatory activities. DBV Technologies Reports Full Year 2025 Financial Results and Business Update
• Neutral Sentiment: Regulatory/filing housekeeping — DBV filed its 2025 Form 10-K and Universal Registration Document (URD), making audited results and governance disclosures available to investors. This is procedural but important for due diligence. DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
• Negative Sentiment: Quarterly results significantly missed expectations: EPS of ($4.43) vs. consensus ($0.19) and revenue $0.64M vs. $1.06M expected — very wide losses and negative margins raise near-term valuation and funding-scenario concerns despite the stated cash runway. DBV Technologies quarterly earnings press release

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.